Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review
نویسندگان
چکیده
منابع مشابه
Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review.
Atrial fibrillation (AF) is an important and potentially modifiable cause of stroke. It has been known since 1989 that oral anticoagulant drugs, such as warfarin, lead to a dramatic decrease in stroke associated with AF. The best risk-benefit ratio is obtained with intensity of oral anticoagulant treatment for an INR of 2-3, even in the elderly. Given the risks of anticoagulant therapy, includi...
متن کاملPatient values and preferences for antithrombotic therapy in atrial fibrillation. A Narrative Systematic Review.
Guidelines recommend that patients' values and preferences should be considered when selecting stroke prevention therapy for atrial fibrillation (SPAF). However, doing so is difficult, and tools to assist clinicians are sparse. We performed a narrative systematic review to provide clinicians with insights into the values and preferences of AF patients for SPAF antithrombotic therapy. Narrative ...
متن کاملAntithrombotic therapy in atrial fibrillation.
Abbreviations: ACUTE 5 Assessment of Cardioversion Using Transesophageal Echocardiography; AF 5 atrial fibrillation; AFASAK 5 Atrial Fibrillation Aspirin and Anticoagulation; AFI 5 Atrial Fibrillation Investigators; BAATAF 5 Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA 5 Canadian Atrial Fibrillation Anticoagulation; CI 5 confidence interval; DC 5 direct current; EAFT 5 Europe...
متن کاملNonvalvular atrial fibrillation and stroke: a review.
Nonvalvular atrial fibrillation accounts for more than thirty percent of all strokes above the age of sixty years. The use of anticoagulants for the primary prevention of stroke has been a controversial issue for a long time. New data has emerged which clarifies some of these issues and helps in selecting patients who are at a higher risk of stroke.
متن کاملAntithrombotic therapy for atrial fibrillation.
Pooled estimate 1 2.5 (1.8-3.5) .59 (for heterogeneity) Studies included in pooled estimate: AFI 2/ 1994 2.5 (NR) , .05 SPAF I-III Aspirin 3/ 1999 2.9 (NR) , .001 Stöllberger et al 4 /1998 3.7 (1.5-7.5) .002 Wang et al 5 /2003 1.9 (1.1-3.3) NR Studies not included in pooled estimate: AFI Echo 6 /1998a 3.5 (1.8-6.7) , .001 Aronow et al 7 /1998 1.6 (1.1-2.2) , .009 Hart et al 8 /2000 (intermitten...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Portuguesa de Cardiologia
سال: 2011
ISSN: 0870-2551
DOI: 10.1016/j.repc.2011.09.014